Trials / Active Not Recruiting
Active Not RecruitingNCT06120075
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 91 (estimated)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AB801 | Administered as specified in the treatment arm |
| DRUG | Docetaxel | Administered as specified in the treatment arm |
Timeline
- Start date
- 2024-01-19
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2023-11-07
- Last updated
- 2026-03-31
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06120075. Inclusion in this directory is not an endorsement.